{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:11:07Z","timestamp":1760148667097,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Fabry cardiomyopathy is characterized by left ventricular hypertrophy, myocardial fibrosis, arrhythmia, and premature death. Treatment with migalastat, an oral pharmacological chaperone, was associated with a stabilization of cardiac biomarkers and a reduction in left ventricular mass index, as measured by echocardiography. A recent study, using cardiac magnetic resonance (CMR) as the gold standard, found a stable course of myocardial involvement after 18 months of treatment with migalastat. Our study aimed to provide long-term CMR data for the treatment with migalastat. Methods: A total of 11 females and four males with pathogenic amenable GLA mutations were treated with migalastat and underwent 1.5T CMR imaging for routine treatment effect monitoring. The main outcome was a long-term myocardial structural change, reflected by CMR. Results: After migalastat treatment initiation, left ventricular mass index, end diastolic volume, interventricular septal thickness, posterior wall thickness, estimated glomerular filtration rate, and plasma lyso-Gb3 remained stable during the median follow-up time of 34 months (min.: 25; max.: 47). The T1 relaxation times, reflecting glycosphingolipid accumulation and subsequent processes up to fibrosis, fluctuated over the time without a clear trend. No new onset of late gadolinium enhancement (LGE) areas, reflecting local fibrosis or scar formation of the myocardium, could be detected. However, patients with initially present LGE showed an increase in LGE as a percentage of left ventricular mass. The median \u03b1-galactosidase A enzymatic activity increased from 37.3% (IQR 5.88\u201389.3) to 105% (IQR 37.2\u2013177) of the lower limit of the respective reference level (p = 0.005). Conclusion: Our study confirms an overall stable course of LVMi in patients with FD, treated with migalastat. However, individual patients may experience disease progression, especially those who present with fibrosis of the myocardium already at the time of therapy initiation. Thus, a regular treatment re-evaluation including CMR is needed to provide the optimal management for each patient.<\/jats:p>","DOI":"10.3390\/life13051213","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T09:23:10Z","timestamp":1684488190000},"page":"1213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1029-085X","authenticated-orcid":false,"given":"Constantin","family":"Gatterer","sequence":"first","affiliation":[{"name":"Department of Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-3827","authenticated-orcid":false,"given":"Dietrich","family":"Beitzke","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senta","family":"Graf","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-994X","authenticated-orcid":false,"given":"Max","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-9921","authenticated-orcid":false,"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-1845","authenticated-orcid":false,"given":"Markus","family":"Ponleitner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Manka","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic and Interventional Radiology and Department of Cardiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fritschi","sequence":"additional","affiliation":[{"name":"University Heart Center, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Alexandre","family":"Krayenbuehl","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Kamm","sequence":"additional","affiliation":[{"name":"Radiology Department, Spital Langenthal, 4900 Langenthal, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-1782","authenticated-orcid":false,"given":"Olivier","family":"Dormond","sequence":"additional","affiliation":[{"name":"Department of Immunology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barbey","sequence":"additional","affiliation":[{"name":"Department of Immunology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7333","authenticated-orcid":false,"given":"Pierre","family":"Monney","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, 8091 Zurich, Switzerland"},{"name":"Division of Internal Medicine, Psychiatric University Hospital Zurich, 8008 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Azevedo, O., Cordeiro, F., Gago, M.F., Miltenberger-Miltenyi, G., Ferreira, C., Sousa, N., and Cunha, D. (2021). Fabry Disease and the Heart: A Comprehensive Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094434"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme Replacement Therapy in Fabry Disease","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry Disease management with migalastat\u2014Outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100786","DOI":"10.1016\/j.ymgmr.2021.100786","article-title":"Long-term follow-up of renal function in patients treated with migalastat for Fabry disease","volume":"28","author":"Bichet","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Hughes","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: Data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10976640009148691","article-title":"Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance","volume":"2","author":"Bellenger","year":"2000","journal-title":"J. Cardiovasc. Magn. Reason."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0895-7061(94)00178-E","article-title":"Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient","volume":"8","author":"Bottini","year":"1995","journal-title":"Am. J. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Camporeale, A., Bandera, F., Pieroni, M., Pieruzzi, F., Spada, M., Bersano, A., Econimo, L., Lanzillo, C., Rubino, M., and Mignani, R. (2023). Effect of Migalastat on cArdiac Involvement in FabRry Disease: MAIORA study. J. Med. Genet.","DOI":"10.1136\/jmg-2022-108768"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagi","volume":"19","author":"Messroghli","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_20","first-page":"87","article-title":"Standardized image interpretation and post-processing in cardiovascular magnetic resonance\u20142020 update","volume":"22","author":"Bluemke","year":"2020","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","article-title":"Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update","volume":"22","author":"Hetzel","year":"2020","journal-title":"J. Cardiovasc. Magn. Reason."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular Events in Patients with Fabry Disease","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: Real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Perretta, F., and Jaurretche, S. (2023). Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?. Healthcare, 11.","DOI":"10.3390\/healthcare11040449"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ehjci\/jey135","article-title":"Progression of myocardial fibrosis in hypertrophic cardiomyopathy: Mechanisms and clinical implications","volume":"20","author":"Raman","year":"2018","journal-title":"Eur. Heart J.\u2013Cardiovasc. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic Cardiomyopathy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12968-022-00859-z","article-title":"Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease: A systematic review and meta-analysis","volume":"24","author":"Ponsiglione","year":"2022","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Monticelli, M., Liguori, L., Allocca, M., Bosso, A., Andreotti, G., Lukas, J., Monti, M.C., Morretta, E., Cubellis, M.V., and Hay Mele, B. (2022). Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095105"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Iacobucci, I., Hay Mele, B., Cozzolino, F., Monaco, V., Cimmaruta, C., Monti, M., Andreotti, G., and Monticelli, M. (2023). Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054548"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/BCJ20190513","article-title":"Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease","volume":"477","author":"Seemann","year":"2020","journal-title":"Biochem. J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Weidemann, F., Jovanovic, A., Herrmann, K., and Vardarli, I. (2022). Chaperone Therapy in Fabry Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031887"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and Pompe disease","volume":"23","author":"Lukas","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2017.09.027","article-title":"Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up","volume":"249","author":"Siegenthaler","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Roy, A., Umar, H., Ochoa-Ferraro, A., Warfield, A., Lewis, N., Geberhiwot, T., and Steeds, R. (2021). Atherosclerosis in Fabry Disease\u2014A Contemporary Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194422"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/5\/1213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:38:17Z","timestamp":1760125097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/5\/1213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["life13051213"],"URL":"https:\/\/doi.org\/10.3390\/life13051213","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2023,5,19]]}}}